Safety and Targeting of Anti-hk2 Antibody in mCRPC

计划入组 27 人 · 首次发布于 2019 年 10 月 4 日

A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer

计划入组 144 人 · 首次发布于 2020 年 11 月 25 日

A Survey to Evaluate the Cardiovascular Risk Status of Subjects With Pre-Diabetes in Hong Kong

计划入组 3,000 人 · 首次发布于 2008 年 11 月 6 日

HK2-VDAC modulators (ViDAC Pharma)

Ace-HK20

HFK2

HK inno.N Corporation

South Korea

CHEERAIN HK LIMITED

Hong Kong, China

HK Surgical Inc.

United States

Vidac Pharma Secures Broad U.S. Patent Protection for Novel Mitochondria-Targeted Cancer Therapy

Vidac Pharma Secures USPTO Patent for Novel Hexokinase 2-Mitochondrial Interaction Modulators

Vidac Pharma Secures Funding for Clinical Trials of Cancer Drug Candidates